TScan Therapeutics, Inc. announced on July 20, 2023, the Board of Directors company appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023, replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023. Dr. MacBeath has been serving as Chief Executive Officer since May 24, 2023. On July 20, 2023, the Board appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023, in which capacity Mr. Silver had previously served.

Mr. Dworak has served as Vice President, Finance since April 2022. He has 15 years of experience in financial infrastructure implementation for clinical and manufacturing operations in the biotechnology and life sciences industries. Prior to joining the Company, Mr. Dworak was the Vice President, Head of Financial Planning and Analysis and Business Operations at AVROBIO, Inc., where he implemented a financial infrastructure and developed processes to enable the annual operating plan, strategic plan, and financial reporting.

Before joining AVROBIO, Mr. Dworak was a Director at Moderna, Inc., where he was a key strategic business partner across multiple therapeutic areas and the finance lead for global vaccines business development. Prior to that, Mr. Dworak held positions of increasing responsibility for various biotech and pharmaceutical companies including Merrimack Pharmaceuticals, Inc., SeraCare Life Sciences Inc. (now LGC Clinical Diagnostics, Inc.), and Boston Scientific Corporation. Mr. Dworak has a MBA from Indiana University, Bloomington, Indiana.